Unit
Genome Integrity, RNA and Cancer (UMR3348)
Thematic areas of research:
Image

To top
Unit
STEPHAN VAGNER / SARAH LAMBERT
Genome Integrity, RNA and Cancer (UMR3348)
The research conducted at the « Genome Integrity, RNA and Cancer » Unit explores multiple aspects of genome dynamics that integrate RNA biology in the context of genome maintenance and expression in normal and pathological situations, including cancer.
Teams
Key figures
25
km from Paris
25
nationalities since 2015
25
INTERNATIONAL EVENTS ORGANISED
Key publications
All publications
-
-
-
The plasticity of mRNA translation during cancer progression and therapy resistanceNature Reviews Cancer
-
-
-
-
-
Proper chromosome alignment depends on BRCA2 phosphorylation by PLK1Nature Communications
-
-
-
Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against CancerClinical Cancer Research
-
-
News
All news
-
Albertas Navickas, using organoids to better understand metastatisNewly arrived at Institut Curie, Albertas Navickas, a new Junior Principal Investigator, is working on breast cancer and preparing to form an RNA, tumor microenvironment and metastasis team, reporting to the Genome integrity, RNA and Cancer unit (CNRS UMR3348/University Paris-Saclay), at Orsay.03/05/2022
-
Une nouvelle approche pour décrypter la dynamique des microtubulesL'Institut Curie vient de développer une nouvelle approche pour optimiser l’analyse de la dynamique du cytosquelette et celle des protéines interagissant avec les microtubules. Elle ouvre des perspectives de compréhension de mécanismes clefs en biologie et de phénomènes pathologiques survenant lors des mutations des protéines associées aux microtubules (MAP).01/02/2022
-
Yolanda Prezado, Carsten Janke, Céline Vallot et Nicolas Manel récompensés par l’Académie des sciencesLe 23 novembre, l’Académie des sciences a remis, lors d'une cérémonie exceptionnelle sous la coupole de l’Institut de France, l’ensemble des prix et médailles qu’elle a attribués en 2021. Quatre chercheurs et médecins de l’Institut Curie ont été distingués. Toutes nos félicitations !25/11/2021
-
Aglaia Therapeutics : une nouvelle start-up de l’Institut Curie et Gustave Roussy lève 4M€ pour combattre la résistance aux thérapies cibléesL’Institut Curie et Gustave Roussy, principaux centres européens de lutte contre le cancer, ont annoncé la création de leur spin-off Aglaia Therapeutics, co-fondée avec le fonds d’investissement Advent France Biotechnology. La start-up vient de lever 4M€ pour le développement de thérapies de nouvelle génération capables de contrer la résistance des cellules tumorales aux thérapies ciblées. Les fonds seront utilisés afin d’accélérer les études précliniques nécessaires à l’identification de son premier candidat médicament à développer en phase clinique.26/09/2021
-
RNA and cancer: the translation process influenced by multiple factorsOver the past few months, it has been garnering attention in the news. The development of therapeutic mRNAs has benefited from more than 20 years of research on mRNA. For instance, Stéphan Vagner’s team at Institut Curie, in collaboration with Caroline Robert, a clinician at Gustave Roussy, has examined the mechanisms regulating the “translation” of mRNA into proteins in cancer for many years.27/09/2021
Job offers
All job offers
-
Institut Curie is a major player in research in France. It consists of a hospital and a research centre with more than 1,000 employees and a strong international presence.
The objective of the Institut Curie Research Centre is to develop fundamental research and to use the knowledge produced to improve the diagnosis, prognosis and treatment of various diseases as part of the continuum between fundamental research and innovation for the benefit of patients. -
Institut Curie is a major player in the research and fight against cancer. It consists of a Hospital group and a Research Center of more than 1000 employees with a strong international representativeness.
The objective of the Research Center is to develop basic research and to use the knowledge produced to improve the diagnosis, prognosis, and therapeutics of cancers as part of the continuum between basic research and innovation serving the patient.